secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001104659-22-113463
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel's fostamatinib misses primary endpoint in Phase 3 COVID-19 trial; p=0.0603
--------------------------------------------------------------------------------

- FOCUS Phase 3 trial of fostamatinib in high-risk hospitalized COVID-19 patients did not meet primary endpoint for days on oxygen (p=0.0603).
- Mean days on oxygen were 6.9 for fostamatinib vs 9.0 for placebo; mortality 4 vs 8 deaths (50% reduction, p=0.4521).
- All prespecified secondary endpoints numerically favored fostamatinib, including ordinal scale change to Day 15 (-2.4 vs -1.9, p=0.0428).
- Safety profile consistent with prior experience; no new safety issues; study supported by U.S. Department of Defense.
- Company evaluating next steps in collaboration with partner, U.S. Department of Defense.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922113463/0001104659-22-113463-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465922113463/tm2229339d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-113463

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer